KalVista Pharmaceuticals Inc Stock News

CAMBRIDGE, Mass.

KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being i

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

KalVista Pharmaceuticals (NASDAQ: KALV ) is trending on popular financial social media right now, but it's not good news. Reportedly, there were safety-related concerns over KalVista's clinical study

KalVista Pharmaceuticals Inc. shares KALV, -1.86% tumbled 26% in premarket trade Tuesday, after the company said it's halting a Phase 2 trial of a treatment for hereditary angioedema, after multiple p

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--EAACI 2022 accepts multiple abstracts from KalVista Pharmaceuticals, Inc.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

KalVista Pharmaceuticals (NASDAQ: KALV ) reported its Q3 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings KalVista Pharmaceuticals beat estimated earnings by 1.08%, reporting an EPS of … Full story available on Benzinga.com

KalVista Pharmaceuticals (KALV) began a phase 3 trial called KONFIDENT evaluating is potential oral drug KVD900 for hereditary angioedema ((HAE)) attacks.HAE is a disorder characterized…

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm

KalVista Pharmaceuticals Inc (KALV) shares closed 0.1% lower than its previous 52 week low, giving the company a market cap of $304M. The stock is currently down 5.9% year-to-date, down 23.2% over the past 12 months, and up 61.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 12.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 990.0% The company's stock price performance over the past 12 months lags the peer average by 45.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

KalVista Pharmaceuticals Inc. (NASDAQ:KALV) shares, rose in value on Friday, 12/17/21, with the stock price up by 0.38% to the previous days close as strong demand from buyers drove the stock to $13.20. Actively observing the price movement in the last trading, the stock closed the session at $13.15, falling within a range of $12.85 KalVista Pharmaceuticals Inc. (NASDAQ: KALV) Is A Blank Check For Growth Read More »